[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![PrismMarketView Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1257318598386696195.png) PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4688 followers
Created: 2025-07-09 17:51:27 UTC

COYA Therapeutics (NASDAQ: COYA) was featured in PharmaVoice’s roundup of emerging ALS drug developers. With a dual-mechanism biologic targeting immune dysregulation, COYA-302 is expected to enter Phase X testing in ALS in 2H 2025.


XXXXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1943005090744566196/c:line.svg)

**Related Topics**
[nasdaq](/topic/nasdaq)
[prism](/topic/prism)

[Post Link](https://x.com/PrismMarketView/status/1943005090744566196)